Serotonin and Amyloidopathy

Completed · Not applicable

Conditions studied: Parkinson's Disease

In brief

The purpose of this study is to determine if changes in brain serotonin affects the accumulation of amyloid in the brain. The investigators will use brain imaging methods to measure the amount of serotonin and amyloid in the brain of individuals with Parkinson's Disease (PD) and otherwise healthy older people. PD participants will undergo repeat brain imaging to assess amyloid accumulation two years after their first brain imaging session. All participants will undergo examinations to assess their motor function, and asked questions to assess their mood and thinking.

Key facts

Study ID: NCT02895932
Run by: University of Michigan
People needed: 27
Starts: 2015-01-01
Expected to finish: 2017-10-01
Last updated by the study team: 2018-09-05

Who can join

Age: 45 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Persons who have been diagnosed with Parkinson disease age 45 years and older are eligible to participate in this study.
Healthy older individuals (ages 60-80) without neurologic problems are eligible to participate.

You may not qualify if…

Individuals using some drugs cannot participate. These include anti-depressant medications, buproprion, or St. John's Wort, as well as dopamine antagonist medications.
Women of childbearing age may not participate.
Individuals unable to have MRI scans because of a pacemaker or metal fragments may not participate.
Individuals with a history of stroke may not participate. People with any contraindication of PET imaging such as previous participation in research procedures involving ionizing radiation may not be eligible to participate in this study.

Where it is running

University of Michigan Health System — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.